Clinical Effects of Hypomethylating Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome Who Received DNA-Damaging Chemotherapy for Metastatic Breast Cancer

The cumulative risk of therapy-related myelodysplastic syndrome (t-MDS) in breast cancer patients exposed to chemotherapy and/or radiotherapy is significantly high compared to that in other cancer patients. This report reviews the use of hypomethylating agents (HMAs) to treat a 57-year-old woman new...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Dong Won, Lee, Soo Jung, Sohn, Sang Kyun, Moon, Joon Ho, Chae, Yee Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933035/
https://www.ncbi.nlm.nih.gov/pubmed/31897338
http://dx.doi.org/10.4048/jbc.2019.22.e50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933035/
https://www.ncbi.nlm.nih.gov/pubmed/31897338
http://dx.doi.org/10.4048/jbc.2019.22.e50

Ejemplares similares